8 completed, 3 recruiting, 2 unknown, 1 not yet recruiting. 15 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 8, Recruiting 3, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Morphological and Microscopic Findings: new trials by email Literature Review of Morphological and Microscopic Findings trials Research Report on Morphological and Microscopic Findings
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma Comprehensive Therapy Based on Tumor Stage, IMRT with Primary Clinical Target Volume Based on Margin Expansion, IMRT with Consensus Primary Clinical Target Volume - Non-metastatic Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Sun Yat-sen University | 568 | 2026-07-24 | 2026-08-19 |
| Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions HPV vaccine, Placebo vaccine - Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vulvar Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vaginal Site | Phase 3 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 984 | 2026-05-01 | 2026-02-27 |
| 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream - Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ | Phase 2 / Phase 3 | Recruiting | Boston University | 200 | 2022-10-15 | 2025-11-28 |
| Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement Placebo for Risankizumab, Risankizumab - Psoriasis | Phase 3 | Completed | AbbVie | 174 | 2021-02-26 | 2024-06-14 |
| Induction Chemotherapy for Locally Recurrent Rectal Cancer Combination drug, Chemoradiotherapy, Surgery locally recurrent rectal cancer - Recurrent Rectal Cancer | Phase 3 | Recruiting | Catharina Ziekenhuis Eindhoven | 364 | 2020-11-13 | 2022-09-06 |
| Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy Bracketing, Neoadjuvant therapy, Post-treatment volume margin resection - Breast Cancer | Phase 3 | Unknown | Mansoura University | 370 | 2019-08-01 | 2021-02-25 |
| REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) VGX-3100, Matched Placebo, CELLECTRA™-5PSP - Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Completed | Inovio Pharmaceuticals | 203 | 2019-02-28 | 2024-10-17 |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) 9vHPV vaccine - Papillomavirus Infections, Uterine Cervical Neoplasms | Phase 3 | Completed | Merck Sharp & Dohme LLC | 201 | 2018-06-29 | 2020-02-25 |
| REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) VGX-3100, Placebo, Electroporation (EP) - Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Completed | Inovio Pharmaceuticals | 201 | 2017-06-28 | 2023-07-27 |
| Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions imiquimod, fluorouracil, questionnaire administration - Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion | Phase 3 | Completed | AIDS Malignancy Consortium | 91 | 2015-12-28 | 2025-07-23 |
| Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions imiquimod, fluorouracil, infrared photocoagulation therapy - Anal Cancer, High-grade Squamous Intraepithelial Lesion | Phase 3 | Completed | AIDS Malignancy Consortium | 4446 | 2014-09-24 | 2024-07-26 |
| Interest of Indocyanine Green in Neoplastic Prostatic Tissue indocyanine green infusion - Prostatic Neoplasms | Phase 3 | Withdrawn | Centre Hospitalier Universitaire de Saint Etienne | 2014-04-01 | 2016-03-10 | |
| Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Fluorescence visualization device - Oral Cancer, High-grade Precancer | Phase 3 | Unknown | University of British Columbia | 200 | 2013-01-01 | 2014-09-10 |
| Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia clinical observation, infrared photocoagulation therapy - Anal Cancer, Neoplasm of Uncertain Malignant Potential | Phase 3 | Completed | AIDS Malignancy Consortium | 120 | 2011-04-01 | 2020-08-04 |
| Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System APTIMA HPV Assay, FDA-Approved HPV DNA Test - Human Papillomavirus Infection | Phase 3 | Completed | Gen-Probe, Incorporated | 12896 | 2008-03-01 | 2017-01-06 |
Squamous Intraepithelial Lesions (7) · Margins of Excision (6) · Papillomavirus Infections (4) · HIV Infections (3) · Uterine Cervical Dysplasia (3) · Anus Neoplasms (2) · Uterine Cervical Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Adenocarcinoma in Situ (1) · Atypical Squamous Cells of the Cervix (1) · Breast Neoplasms (1) · Condylomata Acuminata (1) · Mouth Neoplasms (1) · Precancerous Conditions (1) · Prostatic Neoplasms (1)
Pathological Conditions, Signs and Symptoms (15) · Neoplasms (10) · Genital Diseases (8) · Neoplasms by Site (8) · Urogenital Diseases (8) · Communicable Diseases (5) · Disease Attributes (5) · Infections (5) · Pathologic Processes (5) · Sexually Transmitted Diseases (5) · Sexually Transmitted Diseases, Viral (5) · Virus Diseases (5) · DNA Virus Infections (4) · Female Urogenital Diseases (4)
Fluorouracil (2) · Imiquimod (2) · Light Coagulation (2) · VGX-3100 (2) · Watchful Waiting (2) · Chemoradiotherapy (1) · Drug Combinations (1) · Electroporation (1) · Folfox protocol (1) · IFL protocol (1) · Laser Therapy (1) · Neoadjuvant Therapy (1) · Observation (1) · Papillomavirus Vaccines (1) · Radiotherapy, Intensity-Modulated (1)
AIDS Malignancy Consortium (3) · Inovio Pharmaceuticals (2) · AbbVie (1) · Boston University (1) · Catharina Ziekenhuis Eindhoven (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Gen-Probe, Incorporated (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Mansoura University (1) · Merck Sharp & Dohme LLC (1) · Sun Yat-sen University (1) · University of British Columbia (1)
United States (8) · Puerto Rico (5) · Spain (3) · Argentina (2) · Belgium (2) · Canada (2) · Estonia (2) · Finland (2) · Lithuania (2) · Poland (2) · Portugal (2) · South Africa (2) · Brazil (1) · China (1) · Egypt (1)
Jeffrey Skolnik, MD (2) · Bilal Fawaz, MD (1) · Calum MacAulay, Ph.D (1) · Catherine Poh, DDS, PhD (1) · Donald Anderson, Dr. (1) · Jennifer L Reid, PhD (1) · Joel Palefsky, MD (1) · John Yoo, Dr. (1) · Joseph Dort, Dr. (1) · Judith Michels, MD PhD (1) · Jun Ma, Prof. (1) · Karen Kost, Dr. (1) · Kenneth Berean, Dr. (1) · Kevin Higgins, Dr. (1)
PMID 22026481, PMID 30060087, PMID 33034628, PMID 33594934, PMID 33844623, PMID 35416975, PMID 35704479, PMID 39208985, PMID 40801169
U01CA121947 (3), 2014 (1), 2016 (1), 2017 (1), 2018 (1), UM1CA121947 (1)